Erythromelalgia caused by the missense mutation p.Arg220Pro in an alternatively spliced exon of SCN9A (NaV1.7)

Hum Mol Genet. 2024 Jan 7;33(2):103-109. doi: 10.1093/hmg/ddad152.

Abstract

Erythromelalgia (EM), is a familial pain syndrome characterized by episodic 'burning' pain, warmth, and erythema. EM is caused by monoallelic variants in SCN9A, which encodes the voltage-gated sodium channel (NaV) NaV1.7. Over 25 different SCN9A mutations attributed to EM have been described to date, all identified in the SCN9A transcript utilizing exon 6N. Here we report a novel SCN9A missense variant identified in seven related individuals with stereotypic episodes of bilateral lower limb pain presenting in childhood. The variant, XM_011511617.3:c.659G>C;p.(Arg220Pro), resides in the exon 6A of SCN9A, an exon previously shown to be selectively incorporated by developmentally regulated alternative splicing. The mutation is located in the voltage-sensing S4 segment of domain I, which is important for regulating channel activation. Functional analysis showed the p.Arg220Pro mutation altered voltage-dependent activation and delayed channel inactivation, consistent with a NaV1.7 gain-of-function molecular phenotype. These results demonstrate that alternatively spliced isoforms of SCN9A should be included in all genomic testing of EM.

Keywords: NaV1.7; electrophysiology; erythromelalgia; pain.

MeSH terms

  • Erythromelalgia* / genetics
  • Exons / genetics
  • Humans
  • Mutation
  • Mutation, Missense / genetics
  • NAV1.7 Voltage-Gated Sodium Channel / genetics
  • Pain / genetics

Substances

  • NAV1.7 Voltage-Gated Sodium Channel
  • SCN9A protein, human